Clear Search

Aditya Bardia, MD (MBBS), MPH

University of California

Los Angeles, California

Titles and Affiliations

Director, Breast Cancer Clinical Research Programs
Assistant Chief, Translational Research in the Division of Hematology/Oncology
David Geffen School of Medicine

Director, Translations Research Integration
Co-Director, Breast Cancer Disease Site Group
Jonsson Comprehensive Cancer Center

Research area

Developing more effective and less toxic therapeutic approaches for metastatic triple-negative breast cancer.


Metastatic triple-negative breast cancer (mTNBC) is associated with aggressive tumor biology and lower survival rates. Chemotherapy has been the mainstay of mTNBC treatment and management, but it is not always effective and can be quite toxic. Developing new therapeutic approaches and combinations therefore represents a major unmet clinical need and is essential to providing patients with more effective and less toxic therapies that impact survival.

What’s next

Dr. Bardia and his team recently led the clinical development of a new therapy, sacituzumab govitecan (SG), the first antibody-drug conjugate approved for mTNBC. These novel agents comprise an antibody, which specifically binds to the surface of tumor cells but not to normal cells, and a highly potent drug payload that is selectively delivered to tumor cells. The team is looking to systematically identify biomarkers and understand the pathways governing the response and resistance to SG with the goal of identifying additional targets and further improving outcomes for patients with mTNBC.


Aditya Bardia, MD, MPH, is a board-certified medical oncologist, an Attending Physician at Massachusetts General Hospital (MGH), and an Associate Professor at Harvard Medical School in Boston. As the Director of the Breast Cancer Research Program at MGH, Dr. Bardia is interested in advancing research to improve the outcomes of breast cancer. Dr. Bardia has led the clinical development of an antibody drug conjugate (ADC), sacituzumab govitecan, the first ADC approved for patients with metastatic triple-negative breast cancer. Dr. Bardia has received several research awards, including an outstanding award for research excellence at Mayo Clinic, a Young Investigator Award from ASCO, and the Douglas Family Foundation prize for excellence in oncology research at MGH. Dr. Bardia is the editor of the precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and an editorial board member of the ASCO molecular oncology tumor board.

BCRF Investigator Since


Donor Recognition

The Myra Kraft Award

Areas of Focus

Metastasis Treatment